Доступ предоставлен для: Guest
Ethics in Biology, Engineering and Medicine: An International Journal
Главный редактор: Subrata Saha (open in a new tab)

ISSN Печать: 2151-805X

ISSN Онлайн: 2151-8068

SJR: 0.123

Ethical Issues Involving the Development of COVID-19 Vaccines: Role of Vaccine Development, Clinical Trials, and Speed of Peer Review in Dissuading Public Vaccine Hesitancy

Том 12, Выпуск 1, 2021, pp. 127-140
DOI: 10.1615/EthicsBiologyEngMed.2022043551
Get accessGet access

Краткое описание

Over 60% of the population in the United States received the SARS-Co-V type 2 messenger RNA (mRNA) vaccine, manufactured by Pfizer-BioNTech and by Moderna. The pace at which these mRNA vaccines have been developed may be alarming to the public when compared with timelines for the development of traditional vaccines for other diseases, eliciting issues of mistrust. Ethical issues arise regarding the pace of vaccine development and have been described and highlighted by the media. In addition, testing and validation of basic science and clinical findings, combined with potential side effects of the mRNA vaccines have contributed to public mistrust of this particular vaccine platform. Here, we focus on the current ethical concerns involved with vaccine development, identify the ethical concerns that mitigate the role of public vaccine hesitancy and efforts to minimize the role of such issues, and address some of the scientific concerns cited by the public in their hesitancy to obtain the mRNA vaccine.

ЛИТЕРАТУРА
  1. Graham BS, Mascola JR, Fauci AS. Novel vaccine technologies: Essential components of an adequate response to emerging viral diseases. JAMA. 2018;319(14):1431-2.

  2. Diamond D. FDA approval not swaying some vaccine holdouts. Washington Post [online]. August 25, 2021.

  3. Toy S. Why some health care workers would rather lose their jobs than get vaccinated. Wall Street Journal [online]. October 24, 2021.

  4. Purcell LN, Charles AG. An invited commentary on "World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19)": Emergency or new reality? Int J Surg. 2020;76:111.

  5. Kun A. Time to acceptance of 3 days for papers about COVID-19. Publications 2020;8(2):30. Available from: https://www.mdpi.com/2304-6775/8/2/30?msclkid=57219b3ac65c11ec852882a5dd32ec89.

  6. Himmelstein D. The history of publishing delays. Satoshi Village [blog]; 2016. Available from: https://blog.dhimmel.com/history-of-delays/.

  7. Crowcroft NS, Rosella LC, Pakes BN. The ethics of sharing preliminary research findings during public health emergencies: A case study from the 2009 influenza pandemic. Euro Surveill. 2014;19(24):20831.

  8. Fraser N, Brierley L, Dey G, Polka JK, Palfy M, Nanni F, Coates JA. The evolving role of preprints in the dissemination of COVID-19 research and their impact on the science communication landscape. PLoS Biol. 2021;19(4):e3000959.

  9. Unalp A, Tonascia S, Meinert CL. Presentation in relation to publication of results from clinical trials. Contemp Clin Trials. 2007;28(4):358-69.

  10. Ioannidis JP, Cappelleri JC, Sacks HS, Lau J. The relationship between study design, results, and reporting of randomized clinical trials of HIV infection. Control Clin Trials. 1997;18(5):431-44.

  11. Misakian AL, Bero LA. Publication bias and research on passive smoking: Comparison of published and unpublished studies. JAMA. 1998;280(3):250-3.

  12. Dickersin K, Olson CM, Rennie D, Cook D, Flanagin A, Zhu Q, Reiling J, Pace B. Association between time interval to publication and statistical significance. JAMA. 2002;287(21):2829-31.

  13. Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, McCullough MP, Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ. An mRNA vaccine against SARS-CoV-2 - Preliminary report. N Engl J Med. 2020;383(20):1920-31.

  14. Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Raabe V, Bailey R, Swanson KA, Li P, Koury K, Kalina W, Cooper D, Fontes-Garfias C, Shi PY, Tureci 0, Tompkins KR, Walsh EE, Frenck R, Falsey AR, Dormitzer PR, Gruber WC, Sahin U, Jansen KU. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020;586(7830):589-93.

  15. Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz LM, Vormehr M, Baum A, Pascal K, Quandt J, Maurus D, Brachtendorf S. COVID-19 vaccine BNT162b1 elicits human antibody and TH 1 T cell responses. Nature. 2020;586(7830):594-9.

  16. Broockman D, Kalla J, Guerrero A, Budolfson M, Eyal N, Jewell NP, Magalhaes M, Sekhon JS. Broad cross-national public support for accelerated COVID-19 vaccine trial design. Vaccine. 2021;39:309-16.

  17. Yasui F, Kai C, Kitabatake M, Inoue S, Yoneda M, Yokochi S, Kase R, Sekiguchi S, Morita K, Hishima T, Suzuki H. Prior immunization with severe acute respiratory syndrome (SARS)-associated corona-virus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV. J Immunol. 2008;181(9):6337-48.

  18. Bolles M, Deming D, Long K, Agnihothram S, Whitmore A, Ferris M, Funkhouser W, Gralinski L, Totura A, Heise M, Baric RS. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J Virol. 2011;85(23):12201-15.

  19. Tseng CT, Sbrana E, Iwata-Yoshikawa N, Newman PC, Garron T, Atmar RL, Peters CJ, Couch RB. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PLoS One. 2012;7(4):e35421.

  20. Agrawal AS, Tao X, Algaissi A, Garron T, Narayanan K, Peng BH, Couch RB, Tseng CT. Immunization with inactivated Middle East respiratory syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus. Hum Vaccin Immunother. 2016;12(9):2351-6.

  21. Wang Q, Zhang L, Kuwahara K, Li L, Liu Z, Li T, Zhu H, Liu J, Xu Y, Xie J, Morioka H. Immunodominant SARS coronavirus epitopes in humans elicited both enhancing and neutralizing effects on infection in non-human primates. ACS Infect Dis. 2016;2(5):361-76.

  22. Liu L, Wei Q, Lin Q, Fang J, Wang H, Kwok H, Tang H, Nishiura K, Peng J, Tan Z, Wu T. Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. JCI Insight. 2019;4(4):e123158.

  23. Hotez PJ, Corry DB, Bottazzi ME. COVID-19 vaccine design: The Janus face of immune enhancement. Nat Rev Immunol. 2020;20(6):347-8.

  24. Wan Y, Shang J, Sun S, Tai W, Chen J, Geng Q, He L, Chen Y, Wu J, Shi Z, Zhou Y. Molecular mechanism for antibody-dependent enhancement of coronavirus entry. J Virol. 2020;94(5):e02015-19.

  25. Tan W, Lu Y, Zhang J, Wang J, Dan Y, Tan Z, He X, Qian C, Sun Q, Hu Q, Liu H. Viral kinetics and antibody responses in patients with COVID-19 [Preprint]. MedRxiv. March 26, 2020. doi: 10.1101/2020.03.24.20042382. DOI: 10.1101/2020.03.24.20042382

  26. Jiang HW, Li Y, Zhang HN, Wang W, Yang X, Qi H, Li H, Men D, Zhou J, Tao SC. SARS-CoV-2 proteome microarray for global profiling of COVID-19 specific IgG and IgM responses. Nat Commun. 2020;11(1):3581.

  27. Wu F, Wang A, Liu M, Wang Q, Chen J, Xia S, Ling Y, Zhang Y, Xun J, Lu L, Jiang S. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. Lancet. In press 2020. doi: 10.2139/ssrn.3566211. DOI: 10.2139/ssrn.3566211

  28. Vojdani A, Kharrazian D. Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases. Clin Immunol. 2020;217:108480.

  29. Vojdani A, Vojdani E and Kharrazian D. Reaction of Human Monoclonal Antibodies to SARS-CoV-2 Proteins With Tissue Antigens: Implications for Autoimmune Diseases. Front. Immunol. 2021;11:617089. doi: 10.3389/fimmu.2020.617089. DOI: 10.3389/fimmu.2020.617089

  30. Rosenbaum L. Escaping catch-22: Overcoming COVID vaccine hesitancy. N Engl J Med. 2021;384(14):1367-71.

  31. Ubel PA. What should I do, doc?: Some psychologic benefits of physician recommendations. Arch Intern Med. 2002;162(9):977-80.

  32. Ball LK, Evans G, Bostrom A. Risky business: Challenges in vaccine risk communication. Pediatrics. 1998;101(3):453-8.

  33. U.S. Food & Drug Administration. Emergency use authorization for vaccines to prevent COVID-19: Guidance for industry. March 31, 2022. Available from: https://fda.gov/media/142749/download.

  34. U.S. Food & Drug Administration. Development and licensure of vaccines to prevent COVID-19: Guidance for industry. June 2020. Available from: https://www.fda.gov/media/139638/download.

  35. U.S. Food & Drug Administration. General principles for the development of vaccines to protect against global infectious diseases: Guidance for industry. December 2011. Available from: https:// www.fda.gov/media/82306/download.

  36. Corbett KS, Flynn B, Foulds KE, Francica JR, Boyoglu-Barnum S, Werner AP, Flach B, O'Connell S, Bock KW, Minai M, Nagata BM. Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. N Engl J Med. 2020;383(16):1544-55.

  37. Vogel AB, Kanevsky I, Che Y, Swanson KA, Muik A, Vormehr M, Kranz LM, Walzer KC, Hein S, Guler A, Loschko J, Maddur MS, Ota-Setlik A, Tompkins K, Cole J, Lui BG, Ziegenhals T, Plaschke A, Eisel D, Dany SC, Fesser S, Erbar S, Bates F, Schneider D, Jesionek B, Sanger B, Wallisch AK, Feuchter Y, Junginger H, Krumm SA, Heinen AP, Adams-Quack P, Schlereth J, Schille S, Kroner C, de la Caridad Guimil Garcia R, Hiller T, Fischer L, Sellers RS, Choudhary S, Gonzalez O, Vascotto F, Gutman MR, Fontenot JA, Hall-Ursone S, Brasky K, Griffor MC, Han S, Su AAH, Lees JA, Nedoma NL, Mashalidis EH, Sahasrabudhe PV, Tan CY, Pavliakova D, Singh G, Fontes-Garfias C, Pride M, Scully IL, Ciolino T, Obregon J, Gazi M, Carrion R Jr, Alfson KJ, Kalina WV, Kaushal D, Shi PY, Klamp T, Rosenbaum C, Kuhn AN, Tureci O, Dormitzer PR, Jansen KU, Sahin U. BNT162b vaccines protect rhesus macaques from SARS-CoV-2. Nature. 2021;592(7853):283-9.

  38. Meyer M, Wang Y, Edwards D, Smith GR, Rubenstein AB, Ramanathan P, Mire CE, Pietzsch C, Chen X, Ge Y, Cheng WS. mRNA-1273 efficacy in a severe COVID-19 model: Attenuated activation of pulmonary immune cells after challenge. J Clin Invest. 2021;131(20):e148036.

  39. Rhoads D, Peaper DR, She RC, Nolte FS, Wojewoda CM, Anderson NW, Pritt BS. College of American Pathologists (CAP) Microbiology Committee perspective: Caution must be used in interpreting the cycle threshold (Ct) value. Clin Infect Dis. 2021;72(10):e685-6.

  40. World Health Organization. WHO information notice for IVD users 2020/05 nucleic acid testing (NAT) technologies that use polymerase chain reaction (PCR) for detection of SARS-CoV-2. January 20, 2021. Available from: https://www.who.int/news/ item/20-01-2021-who-information-notice-for-ivd-users-2020-05.

  41. Randolph HE, Barreiro LB. Herd immunity: Understanding COVID-19. Immunity. 2020;52(5):737-41.

  42. Vopp KG, Loewenstein G, Buttenheim AM. Behaviorally informed strategies for a national COVID-19 vaccine promotion program. JAMA. 2021;325(2):125-6.

  43. Succi RCM. Vaccine refusal - what we need to know. J Pediatr. 2018;94(6):574-81.

  44. Dror AA, Eisenbach N, Taiber S, Morozov NG, Mizrachi M, Zigron A, Srouji S, Sela E. Vaccine hesitancy: The next challenge in the fight against COVID-19. Eur J Epidemiol. 2020;35(8):775-9.

  45. Callaghan T, Moghtaderi A, Lueck JA, Hotez P, Strych U, Dor A, Fowler EF, Motta M. Correlates and disparities of intention to vaccinate against COVID-19. Soc Sci Med. 2021;272:113638.

  46. SteelFisher GK, Blendon RJ, Caporello H. An uncertain public - encouraging acceptance of COVID-19 vaccines. N Engl J Med. 2021;384(16):1483-7.

  47. Newman AM. Institutional problems, individual solutions - the burden on Black physicians. New Eng J Med. 2021;384(22):2076-8.

  48. Fisher KA, Bloomstone SJ, Walder J, Crawford S, Fouayzi H, Mazor KM. Attitudes toward a potential SARS-CoV-2 vaccine: A survey of US adults. Ann Intern Med. 2020;173(12):964-73.

  49. Khubchandani J, Sharma S, Price JH, Wiblishauser MJ, Sharma M, Webb FJ. COVID-19 vaccination hesitancy in the United States: A rapid national assessment. J Community Health. 2021;46(2):270-7.

  50. Smith PJ, Chu SY, Barker LE. Children who have received no vaccines: Who are they and where do they live? Pediatrics. 2004;114(1):187-95.

  51. Kim SS, Frimpong JA, Rivers PA, Kronenfeld JJ. Effects of maternal and provider characteristics on up-to-date immunization status of children aged 19 to 35 months. Am J Public Health. 2007;97(2):259-66.

  52. Brewer NT, Fazekas KI. Predictors of HPV vaccine acceptability: A theory-informed, systematic review. Prev Med. 2007;45(2-3):107-14.

  53. Constantine NA, Jerman P. Acceptance of human papillomavirus vaccination among Californian parents of daughters: A representative statewide analysis. J Adolesc Health. 2007;40(2):108-15.

  54. Pearce A, Law C, Elliman D, Cole TJ, Bedford H. Factors associated with uptake of measles, mumps, and rubella vaccine (MMR) and use of single antigen vaccines in a contemporary UK cohort: Prospective cohort study. BMJ. 2008;336(7647):754-7.

  55. Rosenthal SL, Rupp R, Zimet GD, Meza HM, Loza ML, Short MB, Succop PA. Uptake of HPV vaccine: Demographics, sexual history and values, parenting style, and vaccine attitudes. J Adolesc Health. 2008;43(3):239-45.

  56. Ogilvie G, Anderson M, Marra F, McNeil S, Pielak K, Dawar M, McIvor M, Ehlen T, Dobson S, Money D, Patrick DM. A population-based evaluation of a publicly funded, school-based HPV vaccine program in British Columbia, Canada: Parental factors associated with HPV vaccine receipt. PLoS Med. 2010;7(5):e1000270.

  57. O'Leary ST, Nelson C, Duran J. Maternal characteristics and hospital policies as risk factors for non-receipt of hepatitis B vaccine in the newborn nursery. Pediatr Infect Dis. 2012;31(1):1-4.

  58. Centers for Disease Control and Prevention. COVID vaccinations in the United States. Available from: https://covid.cdc.gov/covid-data-tracker/#vaccinations.

  59. Igyarto BZ Jacobsen S, Ndeupen S. Future considerations for the mRNA-lipid nanoparticle vaccine platform. Curr Opin Virol. 2021;48:65-72.

  60. DiPiazza AT, Leist SR, Abiona OM, Moliva JI, Werner A, Minai M, Nagata BM, Bock KW, Phung E, Schafer A, Dinnon III KH. COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge. Immunity. 2021;54(8):1869-82.

  61. Muller L, Andree M, Moskorz W, Drexler I, Walotka L, Grothmann R, Ptok J, Hillebrandt J, Ritchie A, Rabl D, Ostermann PN, Robitzsch R, Hauka S, Walker A, Menne C, Grutza R, Timm J, Adams O, Schaal H. Age-dependent immune response to the Biontech/Pfizer BNT162b2 coronavirus disease 2019 vaccination. Clin Infect Dis. 2021;73(11):2065-72.

  62. Moncunill G, Aguilar R, Ribes M, Ortega N, Rubio R, Salmeron G, Molina MJ, Vidal M, Barrios D, Mitchell RA, Jimenez A, Castellana C, Hernandez-Luis P, Rodo P, Mendez S, Llupia A, Puyol L, Rodrigo Melero N, Carolis C, Majyor A, Izquierdo L, Varela P, Trilla A, Vilella A, Barroso S, Angulo A, Engel P, Tortaiada M, Garcia-Basteiro AL, Dobano C. Determinants of early antibody responses to COVID-19 mRNA vaccines in a cohort of exposed and naive healthcare workers. EBioMedicine 2022;75:103805.

  63. Trogen B, Pirofski LA. Understanding vaccine hesitancy in COVID-19. Med. 2021;2(5):498-501.

  64. Newman AM. Institutional problems, individual solutions-the burden on Black physicians. N Engl J Med. 2021;384(22):2076-8.

  65. Christensen PA, Olsen RJ, Long SW, Subehi S, Davis JJ, Hodiat P, Walley DR, Kinskey JC, Ojeda Saavedra M, Pruitt L, Reppond K, Shyer MN, Cambrie J, Gadd R, Thakur RM, Bataioo A, Mangham R, Pena S, Trinh T, Yerramulli P, Nguyen M, Olson R, Shehal R, Gollihar J, Musser JM. Delta variants of SARS-CoV-2 cause significantly increased vaccine breakthrough COVID-19 cases in Houston, Texas. Am J Pathol. 2021;192(2):320-31.

Последний выпуск

Heroics at the End of Life in Pediatric Cardiac Intensive Care: The Role of the Intensivist in Supporting Ethical Decisions around Innovative Surgical Interventions Mithya Lewis-Newby, Emily Berkman, Douglas S. Diekema, Jonna D. Clark Transplantation for Older Patients with Hematologic Malignancies in 2021: Uncertainty and Ethics in Decision-Making H. Joachim Deeg Exploring the Hippocratic Oath: A Critical Look at Medicine's Oldest Surviving Guide to Medical Ethics D. John Doyle All Sore Eyes and Beasts: Spiritual Care Providers' Role in End-of-Life Existential Distress Debra Josephson Abrams, David B. Brecher, Douglas W. Lane The Ethics of Technology Development and Technology Use David W. Chambers Ethical Challenges of Artificial Intelligence in Health Care: A Narrative Review Aaron T. Hui, Shawn S. Ahn, Carolyn T. Lye, Jun Deng The Goods of Health Care Wade L. Robison The Ethics of Observing Low-Risk Thyroid Cancer Betty Y. Chen, Brendan C. Stack A Sampling of Engineering Ethics Conundrums Intended for Classroom Discussion D. John Doyle Toward a Better Understanding of Risk-Taking in Medical Decision Making David S. Dinhofer, Shweta Agarwal Ethical Issues Involving the Development of COVID-19 Vaccines: Role of Vaccine Development, Clinical Trials, and Speed of Peer Review in Dissuading Public Vaccine Hesitancy Leisha M. A. Martin, Gregory W. Buck Autonomy and Addictive Design Stephen Scales Ethical Implications with the Utilization of Artificial Intelligence in Dentistry Neekita Saudagar, Rafia Jabeen, Pallavi Sharma, Sean Mong, Ram M. Vaderhobli Meeting Report: 9th International Conference on Ethics in Biology, Engineering, and Medicine Subrata Saha, Pamela Saha Index, Volume 12, 2021
Портал Begell Электронная Бибилиотека e-Книги Журналы Справочники и Сборники статей Коллекции Цены и условия подписки Begell House Контакты Language English 中文 Русский Português German French Spain